Editas Medicine, a genome editing company based in Cambridge, Mass, has appointed John D. Mendlein to its board of directors. Mendlein has served as CEO of aTyr Pharma since 2011, as well as executive chairman for the company from July 2010 to January 2016.
Mendlein previously served as CEO of Adnexus Therapeutics, a biopharmaceutical company, from 2005 to 2008. He served as chairman and CEO of Affinium Pharmaceuticals (acquired by Debiopharm Group) from 2000 to 2005, and as a board member, general counsel and chief knowledge officer at Aurora Bioscience Corporation (acquired by Vertex Pharmaceuticals) from August 1996 to September 2001.
Editas was founded in 2013 with $43 million in Series A venture capital financing led by health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund. Editas uses a gene-editing technique called Crispr, which allows genomic researchers snip and edit a wide variety of genomes to correct glitches or insert new codes.
Editas recently went public in an IPO which raised $94.4 million as it priced 5.9 million shares at $16 per share.
Editas’ board of directors consist of Alexis Borisy, Douglas Cole, Kevin Bitterman, Katrine Bosley, Boris Nikolic and Mendlein.